Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Current Assets (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Current Assets for 16 consecutive years, with $15.2 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 188.46% to $15.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.2 million through Dec 2025, up 188.46% year-over-year, with the annual reading at $15.2 million for FY2025, 188.46% up from the prior year.
  • Current Assets for Q4 2025 was $15.2 million at Plus Therapeutics, down from $17.6 million in the prior quarter.
  • The five-year high for Current Assets was $22.1 million in Q1 2022, with the low at $4.2 million in Q1 2024.
  • Average Current Assets over 5 years is $13.9 million, with a median of $13.6 million recorded in 2023.
  • The sharpest move saw Current Assets crashed 69.09% in 2024, then soared 227.85% in 2025.
  • Over 5 years, Current Assets stood at $22.1 million in 2021, then dropped by 1.27% to $21.8 million in 2022, then plummeted by 54.93% to $9.8 million in 2023, then crashed by 46.52% to $5.3 million in 2024, then skyrocketed by 188.46% to $15.2 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $15.2 million, $17.6 million, and $9.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.